Liposomal Clodronate as a Therapy for Autoimmune Hemolytic Anemia
Tech ID: 02-07
NOTE: THIS TECHNOLOGY IS EXPERIMENTAL AND THEREFORE IT IS NOT AVAILABLE TO HUMANS. IT HAS ONLY BEEN TESTED IN MICE AND DOGS DIAGNOSED WITH AIHA
Summary - This invention is using liposomal clodronate as a therapy for autoimmune hemolytic anemia (AIHA).
Therapy for autoimmune hemolytic anemia
The therapy is applicable to both humans and companion animals
Advantages of Invention
The method is less invasive than surgery (splenectomy)
Decrease use of steroids
Decrease side effects
State of Development
The efficacy of this therapy has been demonstrated by some strong in vivo data obtained in mice and dogs with AIHA.
Using a mouse model in which animals were given anti red blood cell antibodies, treatment with liposomal clodronate substantially decreased red blood cell destruction.
In addition, this effect was detected within hours and lasted at least a week.
Further R&D Required - Additional in vivo studies with other animal models.
RBC clearance and the effects of LC treatment in dogs with AIHA. RBC clearance in 6 dogs with spontaneous AIHA was assessed by flow cytometry prior to treatment and again 24 hours after treatment with LC and the mean (± SE) percentage of labeled RBC present in circulation at each time point post infusion was determined. (B) RBC clearance kinetics were determined again 24 hours after treatment with 0.5 mL/kg LC. In 4 dogs (Nonresponders), there was no change in RBC clearance compared to clearance prior to treatment with LC, whereas in 2 dogs (Responders), RBC clearance was markedly reduced.
Jordan, M. B., John Kappler, and Pippa Marrack. "Liposomal Clodronate as a Novel Agent for Treating Autoimmune Hemolytic Anemia in a Mouse Model." Blood 101.2 (2002): 594-601. Print. PMID: 12393630.
Mathes, Mark, Michael Jordan, and Steven Dow. "Evaluation of Liposomal Clodronate in Experimental Spontaneous Autoimmune Hemolytic Anemia in Dogs." Experimental Hematology 34.10 (2006): 1393-402. Print. PMID: 16982332.
Inventors - Mike Jordan, MD, Philippa Marrack, PhD and John Kappler, PhD
Patent Status - U.S. Patent #7,090,865.
Licensing Potential - Available for licensing.
For Further Information, Contact:
Emmanuel Hilaire, PhD
Technology Transfer Office
National Jewish Health
1400 Jackson Street, Room M206b
Denver, CO 80206